Alex Thurman Sells 10,000 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS) CFO Alex Thurman sold 10,000 shares of Glaukos stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $150.00, for a total transaction of $1,500,000.00. Following the transaction, the chief financial officer owned 43,681 shares of the company’s stock, valued at $6,552,150. The trade was a 18.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Glaukos Stock Up 1.3%

GKOS stock opened at $154.91 on Friday. Glaukos Corporation has a twelve month low of $73.16 and a twelve month high of $155.70. The company has a quick ratio of 4.73, a current ratio of 5.43 and a debt-to-equity ratio of 0.10. The firm has a market cap of $9.10 billion, a PE ratio of -47.23 and a beta of 0.75. The business has a 50 day moving average of $131.76 and a 200 day moving average of $120.46.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The business had revenue of $150.57 million during the quarter, compared to analysts’ expectations of $137.00 million. During the same quarter in the previous year, the business earned ($0.22) earnings per share. The firm’s quarterly revenue was up 41.2% compared to the same quarter last year. On average, research analysts forecast that Glaukos Corporation will post -0.57 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on GKOS. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a research report on Tuesday, April 21st. Wall Street Zen raised shares of Glaukos from a “hold” rating to a “buy” rating in a report on Saturday, July 4th. JPMorgan Chase & Co. upped their target price on shares of Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. William Blair reissued an “outperform” rating on shares of Glaukos in a research report on Tuesday, May 26th. Finally, Stifel Nicolaus set a $170.00 price objective on shares of Glaukos in a report on Thursday, April 30th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $151.62.

Institutional Trading of Glaukos

A number of large investors have recently made changes to their positions in GKOS. AQR Capital Management LLC lifted its position in Glaukos by 2.6% during the first quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock valued at $766,000 after purchasing an additional 198 shares during the period. Jones Financial Companies Lllp grew its position in Glaukos by 1,405.9% in the 1st quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock worth $252,000 after purchasing an additional 2,390 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Glaukos by 41.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock worth $22,636,000 after purchasing an additional 67,668 shares during the period. M&T Bank Corp purchased a new stake in Glaukos during the 2nd quarter valued at $203,000. Finally, Gamco Investors INC. ET AL raised its stake in Glaukos by 10.7% during the 2nd quarter. Gamco Investors INC. ET AL now owns 8,001 shares of the medical instruments supplier’s stock valued at $826,000 after buying an additional 773 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.